XML 41 R28.htm IDEA: XBRL DOCUMENT v3.21.2
Collaboration and Other Agreements - I-Mab Biopharma (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Dec. 31, 2019
Dec. 31, 2020
Collaboration And Other Agreements [Line Items]            
Revenues $ 30,757 $ 20,257 $ 47,638 $ 33,939    
Deferred revenue, current 16,565   16,565     $ 4,456
Deferred revenue, net of current portion 13,476   13,476     6,926
I-Mab | I-Mab Biopharma Collaboration and License Agreement            
Collaboration And Other Agreements [Line Items]            
Non-refundable upfront payment         $ 15,000  
Potential development and regulatory milestone payments under agreement         135,000  
Estimated variable consideration         $ 1,000  
Revenues 1,700 $ 1,400 2,300 $ 2,500    
Deferred revenue 9,000   9,000     11,400
Deferred revenue, current 3,400   3,400     4,500
Deferred revenue, net of current portion $ 5,600   $ 5,600     $ 6,900
I-Mab | I-Mab Biopharma Collaboration and License Agreement | Maximum            
Collaboration And Other Agreements [Line Items]            
Potential proceeds from royalties (percent)         20.00%